Introduction
Faecal calprotectin (FCAL) is a useful test for monitoring inflammatory bowel disease (IBD) activity. Providing a stool sample in person to the hospital laboratory is anecdotally unpopular. A new FCAL kit (IBDoc™, Bühlmann) enables selftesting using a proprietary collection tube, camera smartphone and app. The aims of this study were to:
• assess patients' adherence to and experience of using IBDoc™ • compare the assay to the standard laboratory test • determine if IBDoc™ can be used to predict a flare of IBD within four months.
Methods
Patients tested stool using IBDoc™ (figure 1) once a month for four months and provided a standard stool sample to be tested with standard ELISA (Bühlmann).
The following questionnaires were completed before and after testing: GAD-7 (anxiety), PHQ-9 (depression), fig 2) ). 37 patients had at least one paired IBDoc™ and laboratory FCAL result, of which 30 were in remission at the time of the test. To predict a flare within four months IBDoc™ showed greater sensitivity than the laboratory test but a low specificity (table 1) .
Sensitivity Specificity NPV IBDoc™ 89% 33% 88% Laboratory 78% 57% 86% 
Conclusions
Home faecal calprotectin testing demonstrated acceptability with patients, with 85% preferring this to other methods. While IBDoc™ showed only moderate correlation to laboratory FCAL, a negative FCAL of < 100 µg/g by either method is a useful test to exclude a flare within four months. Positive results should be interpreted with caution and repeat testing may be advisable prior to treatment escalation. proprietary Calex™ valve tube is used to collect and prepare a sample for analysis. A predetermined volume is applied to a calibrated test reading strip which is imaged by the App, generating a result which is communicated immediately via web portal to the team.
